Related references
Note: Only part of the references are listed.Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction
Marianna Papaspyridonos et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Long-term correction of diabetes in rats after lentiviral hepatic insulin gene therapy
B. Ren et al.
DIABETOLOGIA (2007)
Delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo by hydrodynamic tail vein injection
Olivia C. Hibbitt et al.
JOURNAL OF GENE MEDICINE (2007)
Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice
Vincent Braunersreuther et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Solution structure of the complex between poxvirus-encoded CC chemokine inhibitor vCCI and human MIP-1β
Li Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice
E Trogan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: A novel form of enzyme replacement therapy for ADA deficiency
Denise A. Carbonaro et al.
MOLECULAR THERAPY (2006)
Lentiviral shRNA silencing of murine bone marrow cell CCR2 leads to persistent knockdown of CCR2 function in vivo
I Bot et al.
BLOOD (2005)
In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies
A Lamikanra et al.
GENE THERAPY (2005)
Hydrodynamic liver gene transfer mechanism involves transient sinusoidal blood stasis and massive hepatocyte endocytic vesicles
A Crespo et al.
GENE THERAPY (2005)
Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector
H Kobayashi et al.
MOLECULAR THERAPY (2005)
Hyrodynamics-based procedure involves transient hyperpermeability in the hepatic cellular membrane: implication of a nonspecific process in efficient intracellular gene delivery
N Kobayashi et al.
JOURNAL OF GENE MEDICINE (2004)
Hydroporation as the mechanism of hydrodynamic delivery
G Zhang et al.
GENE THERAPY (2004)
Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice
CA Bursill et al.
CIRCULATION (2004)
Stable transgene expression in tumors and metastases after transduction with lentiviral vectors based on human immunodeficiency virus type 1
LL Bao et al.
HUMAN GENE THERAPY (2004)
In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors
M De Palma et al.
HUMAN GENE THERAPY (2003)
Gene therapy progress and prospects: adenoviral vectors
JA St George
GENE THERAPY (2003)
Myeloid cell function in MRP-14 (S100A9) null mice
JAR Hobbs et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Synthetic mycoplasma-derived lipopeptide MALP-2 induces maturation and function of dendritic cells
H Weigt et al.
IMMUNOBIOLOGY (2003)
Comprehensive mapping of poxvirus vCCI chemokine-binding protein - Expanded range of ligand interactions and unusual dissociation kinetics
JM Burns et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus and activation-regulated chemokine, are expressed in human atherosclerotic lesions
DR Greaves et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
Long-term expression of human alpha 1-antitrypsin gene in mouse liver achieved by intravenous administration of plasmid DNA using a hydrodynamics-based procedure
G Zhang et al.
GENE THERAPY (2000)
A stable system for the high-titer production of multiply attenuated lentiviral vectors
N Klages et al.
MOLECULAR THERAPY (2000)
Share Paper
